FMIBlog16h
Global Leukemia Therapeutics Market Poised for Significant Growth USD 33.1 Billion by 2035, Amid Advancements in Targeted Therapies | FMI
The global leukemia therapeutics treatment market is expected to grow at a CAGR of 6.6% during the forecast period (2025–2035). Factors such as the rising prevalence of leukemia, increasing adoption ...
BREYANZI Demonstrates Continued Growth in the Competitive CAR-T Market | DelveInsight
DelveInsight's 'BREYANZI Market Size, Forecast, and Market Insight Report' highlights the details around BREYANZI, a CD19-directed CAR ...
Acute Myeloid Leukemia Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
In March 2025, Akeso initiated an open-label, Phase Ib/II study involving patients diagnosed with acute myeloid leukemia (AML ...
Narrow-Moat Genmab Benefits From Strong Demand for Darzalex as Pipeline Makes Progress
We believe Genmab is in solid financial health. At the end of 2024, Genmab held DKK 9.9 billion in cash and cash equivalents. After turning profitable in 2013, the company has steadily increased its ...
Wall Street Journal20d
Bristol Myers Squibb Co. Rt
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Investing20d
Companhia Celg de Participacoes Celgpar (GPAR3)
Featured here, the Balance Sheet for Companhia Celg de Participacoes Celgpar, which summarises the company's financial position including assets, liabilities and shareholder equity for each of the ...
ascopubs.org28d
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
F.L.L. is supported by the Leukemia and Lymphoma Society as a Clinical Scholar, and the NCI (R01CA244328, P30-CA076292). S.S. is supported by Stanford Clinical and Translational Science KL2 Career ...